BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

775 related articles for article (PubMed ID: 23571149)

  • 1. What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy?
    van Dam L; Korfage IJ; Kuipers EJ; Hol L; van Roon AH; Reijerink JC; van Ballegooijen M; van Leerdam ME
    Eur J Cancer; 2013 Jul; 49(10):2321-30. PubMed ID: 23571149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy.
    Hol L; de Jonge V; van Leerdam ME; van Ballegooijen M; Looman CW; van Vuuren AJ; Reijerink JC; Habbema JD; Essink-Bot ML; Kuipers EJ
    Eur J Cancer; 2010 Jul; 46(11):2059-66. PubMed ID: 20621736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing different strategies for colorectal cancer screening in Italy: predictors of patients' participation.
    Senore C; Armaroli P; Silvani M; Andreoni B; Bisanti L; Marai L; Castiglione G; Grazzini G; Taddei S; Gasperoni S; Giuliani O; Malfitana G; Marutti A; Genta G; Segnan N
    Am J Gastroenterol; 2010 Jan; 105(1):188-98. PubMed ID: 19826409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low priority main reason not to participate in a colorectal cancer screening program with a faecal occult blood test.
    van Rijn AF; van Rossum LG; Deutekom M; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
    J Public Health (Oxf); 2008 Dec; 30(4):461-5. PubMed ID: 18716047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal cancer screening behavior in women attending screening mammography: longitudinal trends and predictors.
    Carlos RC; Fendrick AM; Abrahamse PH; Dong Q; Patterson SK; Bernstein SJ
    Womens Health Issues; 2005; 15(6):249-57. PubMed ID: 16325138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening.
    DeBourcy AC; Lichtenberger S; Felton S; Butterfield KT; Ahnen DJ; Denberg TD
    J Gen Intern Med; 2008 Feb; 23(2):169-74. PubMed ID: 18157581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy.
    Hol L; van Leerdam ME; van Ballegooijen M; van Vuuren AJ; van Dekken H; Reijerink JC; van der Togt AC; Habbema JD; Kuipers EJ
    Gut; 2010 Jan; 59(1):62-8. PubMed ID: 19671542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
    Tsoi KK; Ng SS; Leung MC; Sung JJ
    Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
    Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
    J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Offering people a choice for colorectal cancer screening.
    Senore C; Ederle A; Benazzato L; Arrigoni A; Silvani M; Fantin A; Fracchia M; Armaroli P; Segnan N
    Gut; 2013 May; 62(5):735-40. PubMed ID: 22442162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of previous non-participants cannot fully compensate for lower participation in a second round of FIT-screening.
    Denters MJ; Deutekom M; Bossuyt PM; van Rijn AF; Fockens P; Dekker E
    Cancer Epidemiol; 2013 Jun; 37(3):330-5. PubMed ID: 23403127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for colorectal cancer: sense and sensibilities.
    Van Hal G; Hoeck S; Van Roosbroeck S
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S156-63. PubMed ID: 21943969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for colorectal cancer screening.
    Bretthauer M
    Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):417-25. PubMed ID: 20833346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
    Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
    Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferences for colorectal cancer screening techniques and intention to attend: a multi-criteria decision analysis.
    Hummel JM; Steuten LG; Groothuis-Oudshoorn CJ; Mulder N; Ijzerman MJ
    Appl Health Econ Health Policy; 2013 Oct; 11(5):499-507. PubMed ID: 23979875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Would general practitioners support a population-based colorectal cancer screening programme of faecal-occult blood testing?
    Tong S; Hughes K; Oldenburg B; Del Mar C
    Intern Med J; 2004; 34(9-10):532-8. PubMed ID: 15482265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of self-reported history of colorectal cancer screening.
    Khoja S; McGregor SE; Hilsden RJ
    Can Fam Physician; 2007 Jul; 53(7):1192-7. PubMed ID: 17872816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faecal occult blood testing (FOBT)-based colorectal cancer screening trends and predictors of non-use: findings from the South Australian setting and implications for increasing FOBT uptake.
    Todorov K; Wilson C; Sharplin G; Corsini N
    Aust Health Rev; 2018 Feb; 42(1):45-52. PubMed ID: 28248632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.